Introduction Malaria, a devastating febrile illness caused by protozoan parasites, sickened
247,000,000 people in 2021 and killed 619,000, mostly children and pregnant women in …

Control measures have significantly reduced malaria morbidity and mortality in the last two
decades; however, the downward trends have stalled and have become complicated by the …

Malaria is a deadly disease responsible for between 550,000 and 627,000 deaths annually.
There is a pressing need to develop vaccines focused on malaria elimination. The complex …

Summary Pfs230 domain 1 (Pfs230D1) is an advanced malaria transmission-blocking
vaccine antigen demonstrating high functional activity in clinical trials. However, the …

Malaria transmission-blocking vaccines (TBVs) aim to induce antibodies that interrupt
malaria parasite development in the mosquito, thereby blocking onward transmission, and …

A malaria vaccine that blocks parasite transmission from human to mosquito would be a
powerful method of disrupting the parasite lifecycle and reducing the incidence of disease in …

An effective malaria vaccine remains a global health priority and vaccine immunogens
which prevent transmission of the parasite will have important roles in multi-component …

Pfs230 is essential for Plasmodium falciparum transmission to mosquitoes and is the protein
targeted by the most advanced malaria-transmission-blocking vaccine candidate. Prior …

Monoclonal antibodies are highly specific proteins that are cloned from a single B cell and
bind to a single epitope on a pathogen. These laboratory-made molecules can serve as …

Malaria is an infectious disease transmitted by mosquitos, whose control is hampered by
drug resistance evolution in the causing agent, protist parasites of the genus Plasmodium …